Episode 14. MRD in Multiple Myeloma

In this episode, we delve into MRD in myeloma with Dr. Luciano Costa and discuss the data for 3 key clinical implications: MRD as a prognostic biomarker, MRD as a tool for treatment modification, and MRD as a surrogate endpoint for drug approval.

Show Notes

1.      Excellent paper on harmonization of performing and reporting MRD in multiple myeloma:
         https://www.nature.com/articles/s41375-020-01012-4

2.     Does CR really matter in the era of MRD? Landmark paper from the Spanish Group:
        https://pubmed.ncbi.nlm.nih.gov/35560160/

3.     Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma:
        https://pubmed.ncbi.nlm.nih.gov/33284948/

4.     MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma :
        https://pubmed.ncbi.nlm.nih.gov/34898239/

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk